Log in

NASDAQ:ALTH - Allos Therapeutics Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Allos Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of anti-cancer therapeutics. As of December 31, 2011, the Company focused on the development and commercialization of FOLOTYN (pralatrexate injection). FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:ALTH
Previous Symbol
CUSIPN/A
CIK1097264
Webhttp://www.allos.com/
Phone+1-303-4266262

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive ALTH News and Ratings via Email

Sign-up to receive the latest news and ratings for ALTH and its competitors with MarketBeat's FREE daily newsletter.


Allos Therapeutics (NASDAQ:ALTH) Frequently Asked Questions

What is Allos Therapeutics' stock symbol?

Allos Therapeutics trades on the NASDAQ under the ticker symbol "ALTH."

Has Allos Therapeutics been receiving favorable news coverage?

News stories about ALTH stock have been trending extremely negative on Monday, according to InfoTrie. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Allos Therapeutics earned a news impact score of -4.5 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Allos Therapeutics.

What other stocks do shareholders of Allos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allos Therapeutics investors own include InterDigital Wireless (IDCC), Hi-Tech Pharmacal (HITK), DryShips (DRYS), Depomed (DEPO), Hongli Clean Energy Technologies (CETC), Cascadian Therapeutics (CASC), Biostar Pharmaceuticals (BSPM), AXT (AXTI), AudioCodes (AUDC) and Amtech Systems (ASYS).

What is Allos Therapeutics' official website?

The official website for Allos Therapeutics is http://www.allos.com/.

How can I contact Allos Therapeutics?

Allos Therapeutics' mailing address is 11080 Circle Point Rd Ste 200, WESTMINSTER, CO 80020-2778, United States. The biopharmaceutical company can be reached via phone at +1-303-4266262.


MarketBeat Community Rating for Allos Therapeutics (NASDAQ ALTH)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  53 (Vote Outperform)
Underperform Votes:  92 (Vote Underperform)
Total Votes:  145
MarketBeat's community ratings are surveys of what our community members think about Allos Therapeutics and other stocks. Vote "Outperform" if you believe ALTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/27/2020 by MarketBeat.com Staff

Featured Article: Stocks at 52 Week High
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel